

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Reich Kristian</u> <hr/> (Last) (First) (Middle) C/O MOONLAKE IMMUNOTHERAPEUTICS DORFSTRASSE 29 <hr/> (Street) ZUG V8 6300 <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>MoonLake Immunotherapeutics [MLTX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Scientific Officer</u>
	3. Date of Earliest Transaction (Month/Day/Year) 02/14/2024	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
Rule 10b5-1(c) Transaction Indication <input checked="" type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Class A ordinary shares, par value \$0.0001 per share	02/14/2024		s ⁽¹⁾		10,000	D	\$62.42 ⁽²⁾	3,017,483	I	See footnote. ⁽³⁾
Class A ordinary shares, par value \$0.0001 per share	02/14/2024		s ⁽¹⁾		10,000	D	\$62.43 ⁽⁴⁾	130,071	D	
Class A ordinary shares, par value \$0.0001 per share	02/15/2024		s ⁽¹⁾		10,000	D	\$60.17 ⁽⁵⁾	3,007,483	I	See footnote. ⁽³⁾
Class A ordinary shares, par value \$0.0001 per share	02/15/2024		s ⁽¹⁾		10,000	D	\$60.16 ⁽⁶⁾	120,071	D	
Class A ordinary shares, par value \$0.0001 per share	02/16/2024		s ⁽¹⁾		10,000	D	\$60.15 ⁽⁷⁾	2,997,483	I	See footnote. ⁽³⁾
Class A ordinary shares, par value \$0.0001 per share	02/16/2024		s ⁽¹⁾		10,000	D	\$60.15 ⁽⁸⁾	110,071	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)					

Explanation of Responses:

- This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.
- The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from \$61.82 to \$63.01. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.
- The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from \$61.82 to \$63.01. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from \$58.10 to \$63.95. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from \$58.18 to \$63.95. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from \$59.34 to \$61.17. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from \$59.34 to \$61.17. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

/s/ Matthias Bodenstedt,
 Attorney-in-fact for Kristian Reich 02/16/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.